FDA Approved: HEPARIN SODIUM — Supplemental Application (Sagent Pharmaceuticals)

View source ↗

Summary

FDA approved a supplemental application for HEPARIN SODIUM from Sagent Pharmaceuticals, authorizing changes under an approved supplemental filing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Deep Venous Thrombosis
• Myocardial Infarction
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• HEPARIN SODIUM (HEPARIN SODIUM)

Snippet

SUPPL AP for HEPARIN SODIUM (HEPARIN SODIUM)